Inflection Biosciences Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 10
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $367K
Latest Deal Amount
  • Investors
  • 3

Inflection Biosciences General Information

Description

Developer of small molecule therapeutics intended to help in the treatment of cancer. The company's therapeutics carries the potential for application in a range of treatments for solid tumors and hematological malignancies, enabling healthcare providers to treat their patients in an enhanced way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 1000 Massachusetts Avenue
  • Cambridge, MA 02138
  • United States
+1 (857) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Inflection Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 11-Aug-2019 $367K 00.00 00.000 Completed Pre-Clinical Trials
3. Later Stage VC 10-Apr-2018 000 00.000 00.000 Completed Pre-Clinical Trials
2. Early Stage VC 09-Mar-2015 $913K $1.53M 00.000 Completed Pre-Clinical Trials
1. Seed Round 04-Jun-2013 $615K $615K Completed Startup
To view Inflection Biosciences’s complete valuation and funding history, request access »

Inflection Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
To view Inflection Biosciences’s complete cap table history, request access »

Inflection Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of small molecule therapeutics intended to help in the treatment of cancer. The company's therapeutics carries
Drug Discovery
Cambridge, MA
10 As of 2022
00.00
0.000 0000-00-00
0000000000 0 00.00

000000

ptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proid
0000 000000000
Seattle, WA
00 As of 0000
00000
0000000000 0 00000

00000000

uptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proi
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Inflection Biosciences Competitors (23)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kineta Venture Capital-Backed Seattle, WA 00 00000 0000000000 0 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000000 00000000000 Formerly VC-backed Lexington, MA 00 00000 00000000 00000
0000000 000000 Venture Capital-Backed Barcelona, Spain 00 0000 000000000000 0000
You’re viewing 5 of 23 competitors. Get the full list »

Inflection Biosciences Executive Team (6)

Name Title Board Seat Contact Info
Darren Cunningham Co-Founder, Chief Executive Officer & Board Member
Gemma Carroll Financial Controller
Michael O'Neill Ph.D Co-Founder, Director of Research and Development & Board Member
Shaun McNulty Ph.D Chief Scientific Officer
Murray Yule Ph.D Chief Medical Officer
You’re viewing 5 of 6 executive team members. Get the full list »

Inflection Biosciences Board Members (7)

Name Representing Role Since
Conor Mallaghan Self Board Member 000 0000
Darren Cunningham Inflection Biosciences Co-Founder, Chief Executive Officer & Board Member 000 0000
Gregory I. Berk MD Self Board Member 000 0000
John Lynch Self Board Member 000 0000
Michael O'Neill Ph.D Inflection Biosciences Co-Founder, Director of Research and Development & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Inflection Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inflection Biosciences Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Fountain Healthcare Partners Venture Capital Minority 000 0000 000000 0
Michael Smurfit Angel (individual) Minority 000 0000 000000 0
Enterprise Ireland Venture Capital Minority 000 0000 000000 0
To view Inflection Biosciences’s complete investors history, request access »